At any one time the University of Oxford sponsors around 1,000 academic designed and led clinical research studies within the EU of which about 150 are interventional trials ranging from phase I to phase IV. The University sponsors approximately 350 further studies outside the EU, largely through its Centre for Tropical Medicine and Global Health.
Often in partnership with Oxford University Hospitals Foundation NHS Trust or Oxford Health Foundation NHS Trust most of the EU-based studies are run by one of the University’s six UKCRC fully registered specialist clinical trials units:
- Clinical Trial Service Unit and Epidemiological Studies Unit specializing in major large scale studies and trials of chronic disease;
- Diabetes Trials Unit national and multinational trials of the management and treatment of diabetes;
- Oxford Clinical Trials Research Unit which integrates the following trials groups:
- Centre for Statistics in Medicine
- Critical Care, Trauma and Rehabilitation Trials Group
- Gastroenterology Trials Group
- Oncology Clinical Trials Office (all phases)
- Respiratory Trials Unit
- Surgical Intervention Trials Unit (SITU)
- NPEU Clinical Trials Unit conducts multicentre trials of a broad range of interventions for women and their families during pregnancy, childbirth, the newborn period and early childhood;
- Primary Care and Vaccines Collaborative Clinical Trials Unit which integrates the Primary Care Trials Unit and the Oxford Vaccine Group
c. 1,000 academic designed and led clinical research studies within the EU
Approximately 350 further studies outside the EU
Clinical Trials News
26 March 2021
The University of Oxford is launching a study investigating the delivery of the ChAdOx1 nCoV-19 coronavirus vaccine using a nasal spray.
25 March 2021
Our partners AstraZeneca have today announced the high-level results from the primary analysis of their Phase III trial of the ChAdOx1 nCoV-19 coronavirus vaccine in the US. They confirm that the vaccine efficacy is consistent with the interim analysis results announced on Monday 22 March 2021.
22 March 2021
A Phase III study of the Oxford-AstraZeneca coronavirus vaccine conducted by AstraZeneca plc in the USA, Chile and Peru has shown that vaccine is safe and highly effective, adding to previous trial data from the United Kingdom, Brazil and South Africa, as well as real-world impact data from the United Kingdom.